The global sickle cell disease drug market is anticipated to grow at a considerable CAGR during the forecast period. The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in June 2020, Emmaus Medical Inc. has received approval from the Israeli Ministry of Health for the commercial distribution of Endari in Israel. Endari is an L-Glutamine oral powder that is used to treat acute complications of sickle cell disease in adults and children age 5 years and older. Further, in October 2020, Medunik USA Inc. launched Siklos for pediatric patients with sickle cell diseases. Siklos is a 100 mg film-coated tablet, that is used to reduce the painful crisis caused by sickle cell disease. According to Medunik USA Inc., skilos are anticipated to reduce the need for blood transfusions. Similarly, in October 2020, the European Commission (EC) has approved the Adakveo drug for commercialization.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/sickle-cell-disease-drug-market
Moreover, in October 2020, the US Food and Drug Administration has approved Rivipansel (GMI-1070) for the treatment of sickle cell disease. Rivipansel is developed by GlycoMemitics in partnership with Pfizer. The revipansel is used to treat the pain crisis, sickle cell disease, and sickle cell-related disorders. Further in January 2022, Sangamo Therapeutics Inc. has developed SAR445136, a zinc finger nuclease gene-edited cell therapy. Sanofi will be transitioning its rights and obligation related to SAR445136. In November 2019, Novartis AG has launched Adkaveo. Adakveo (Crizanlizumab –tmca) is indicated to reduce the Vasco-occlusive crisis in adults and pediatric patients aged 16 years and older.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
- By Treatment
- By End-User
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Novartis AG, Global Blood Therapeutics Inc., Medunik USA Inc., Bristol-Myers Squibb Co, Emmaus Medical Inc., and more
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Sickle Cell Disease Drug Market Report Segment
By Treatment
- Blood Infusion Treatment
- Bone Marrow Transplant
- Pharmacotherapy
By End-User
- Specialty clinic
- Hospitals
A full report of Sickle Cell Disease Drug Market is available at: https://www.omrglobal.com/industry-reports/sickle-cell-disease-drug-market
Sickle Cell Disease Drug Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Alnylam Pharmaceuticals, Inc.
- Arena Pharmaceuticals, Inc.
- AstraZeneca Plc.
- Acceleron Pharma, Inc.
- Bluebird bio, Inc.
- Baxter International, Inc.
- Daiichi Sankyo Co.
- Reddy’s Laboratories, Ltd.
- Eli Lilly &Co.
- Johnson & Johnson Services, Inc.
- SANOFI
- Sangamo Therapeutics, Inc.
- Novartis AG
- Takeda Pharmaceutical Co., Ltd.
